Prosthetic Joint Infections Pipeline Insight
DelveInsight’s, “Prosthetic joint infections – Pipeline Insight, 2020,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Prosthetic joint infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Prosthetic joint infections Understanding
Prosthetic joint infections: Overview
Prosthetic joint infection (PJI), also referred to as periprosthetic infection, is defined as infection involving the joint prosthesis and adjacent tissue. It is a tremendous burden for individual patients as well as the global health care industry. The majority of PJIs occurring within 1 year of surgery are initiated through the introduction of microorganisms at the time of surgery. This can occur through either direct contact or aerosolized contamination of the prosthesis or periprosthetic tissue. Once in contact with the surface of the implant, microorganisms colonize the surface of the implant. A significant factor in this process is the low inoculum of microorganisms needed to establish infection in the presence of the prosthetic material.
Contiguous spread of infection from an adjacent site is the second mechanism by which infection can be initiated. In the early postoperative time period, superficial surgical site infection can progress to involve the prosthesis, due to incompletely healed superficial and deep fascial planes. However, contiguous spread may also occur later if the normal tissue plane is again disrupted through trauma or surgery at an adjacent location. Erosion of the implant through an impaired soft tissue envelope may also predispose patients to a late onset of contiguous infection. This may occur in patients with elbow prostheses and underlying rheumatoid arthritis who may have an adjacent rheumatoid nodule or thin skin due to chronic corticosteroid use.
The diagnosis of PJI is based upon a combination of clinical findings, laboratory results from peripheral blood and synovial fluid, microbiological data, histological evaluation of periprosthetic tissue, intraoperative inspection, and, in some cases, radiographic results. There is no one test or finding that is 100% accurate for PJI diagnosis. The general approach to PJI diagnosis is 2-fold. First, the question as to whether or not the joint is infected must be answered; second, if PJI is present, the causative microorganism(s) must be identified, and, in most cases, its antimicrobial susceptibility must be determined. Test performance may vary with joint type and also with timing post-arthroplasty implantation; where data are available that addresses this, they will be presented.
Successful management of PJI requires surgical intervention and medical therapy in the majority of cases. The goals of PJI treatment are to eradicate the infection, restore pain-free function of the infected joint, and minimize PJI-related morbidity and mortality for the patient. The goal of surgical strategy is to remove all infected tissue and hardware or to decrease the burden of biofilm if any prosthetic material is retained, such that postoperative antimicrobial therapy can eradicate the remaining infection. Antibiotics should be withheld until multiple intraoperative specimens are sent for microbiological analysis, unless the patient requires antimicrobials to treat a systemic infection.
Prosthetic joint infections Emerging Drugs Chapters
This segment of the Prosthetic joint infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Prosthetic joint infections Emerging Drugs
- CF-296: ContraFect Corporation
ContraFect Corporation have developed a novel, engineered variant of exebacase, CF-296, with potential as a targeted therapy for deep-seated, invasive biofilm-associated Staph aureus infections such as prosthetic joint infections. It is currently in preclinical stage of development.
- AP-PA02: Armata Pharmaceuticals
AP-PA02 is being developed as a replacement for its predecessor AP-PA01 (previously known as AB-PA01). A total of 10 patients with serious or life-threatening P. aeruginosa infections not responding to antibiotic therapy have been treated with AP-PA01, along with antibiotics, under single-patient expanded access programs in the United States (Emergency INDs, per the FDA) or Australia (Special Access Scheme, per the Australian Therapeutic Goods Administration). The treated patients’ infections included bacteremia, native and prosthetic valve endocarditis, recurrent pneumonia (CF, post-transplant), VAP, prosthetic joint infection, ventricular assist device infection, and septicemia due. It is in preclinical stage of development.
PLG0206 was developed utilizing Peptilogics’ novel eCAP (engineered cationic antibiotic peptide) platform. This technology dramatically amplifies the antimicrobial activity found in naturally occurring peptides while at the same time potentially delivering an improved systemic safety profile. In preclinical studies, PLG0206 eliminated a variety of biofilm-associated bacteria, including methicillin-sensitive (MSSA) and methicillin-resistant (MRSA) Staphylococcus aureus clinical isolates, sterilizing implants following short exposure in a biofilm model, suggesting that it could rapidly kill implant-associated biofilm bacteria in a clinical setting.
- TNP-2092: TenNor Therapeutics
TNP-2092 is a multi-targeting New Molecular Entity specifically designed for the treatment of infections associated with bacterial biofilms. The compound exhibits potent activity against major pathogens associated with PJIs, including those resistant to the available antibiotics, and shows low propensity for development of resistance. The compound demonstrats excellent activity in various in vitro and in vivo infection models associated with bacterial biofilms. It is currently in phase II stage of development.
Further product details are provided in the report……..
Prosthetic joint infections: Therapeutic Assessment
This segment of the report provides insights about the different Prosthetic joint infections drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Prosthetic joint infections
There are approx. 5+ key companies which are developing the therapies for Prosthetic joint infections. The companies which have their Prosthetic joint infections drug candidates in the most advanced stage, i.e. phase II include TenNor Therapeuticsand and others
DelveInsight’s report covers around 5+ products under different phases of clinical development like
- Late-stage products (Phase II and Phase II/III)
- Mid-stage products (Phase II and Phase II/III)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Prosthetic joint infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Gene therapies
- Small molecule
- Monoclonal antibodies
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Prosthetic joint infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Prosthetic joint infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Prosthetic joint infections drugs.
- The companies and academics are working to assess challenges and seek opportunities that could influence Prosthetic joint infections R&D. The therapies under development are focused on novel approaches to treat/improve Prosthetic joint infections.
- In January 2020, The Food and Drug Administration (FDA) has granted Orphan Drug designation to TNP-2092 (TenNor Therapeutics) powder for intravenous (IV) injection for the treatment of prosthetic joint infections.
- TenNor has also received FDA Qualified Infectious Disease Product (QIDP) and Fast Track designations for TNP-2092. Additionally, TenNor has completed a Phase II clinical trial for TNP-2092 in the United States for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and received positive results.
Prosthetic joint infections Report Insights
- Prosthetic joint infections Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Prosthetic joint infections Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Prosthetic joint infections drugs?
- How many Prosthetic joint infections drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Prosthetic joint infections?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Prosthetic joint infections therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Prosthetic joint infections and their status?
- What are the key designations that have been granted to the emerging drugs?
- ContraFect Corporation
- Armata Pharmaceuticals
- TenNor Therapeutics
- Telephus Medical LLC
- Research programme: monoclonal antibody